Ionis Pharmaceuticals Inc
IONS
View Detailed Chart
81.540USD
-1.630-1.96%
Close 01/08, 16:00（ET）Quotes delayed by 15 min
13.14BMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-1.96%
5 Days
+3.07%
1 Month
+0.04%
6 Months
+97.24%
Year to Date
+3.07%
1 Year
+139.12%
View Detailed Chart
TradingKey Stock Score of Ionis Pharmaceuticals Inc
Currency: USD Updated: 2026-01-08Key Insights
Ionis Pharmaceuticals Inc's fundamentals are relatively stable, and its growth potential is high.Its valuation is considered fairly valued, ranking 17 out of 396 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 86.54.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Ionis Pharmaceuticals Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Ionis Pharmaceuticals Inc Highlights
StrengthsRisks
Ionis Pharmaceuticals, Inc. develops six marketed medicines for serious diseases, including medicines for neurologic and cardiovascular diseases. Its marketed medicines consist of TRYNGOLZA, WAINUA (eplontersen), SPINRAZA (nusinersen), QALSODY (tofersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen). TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS). WAINUA is approved for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults. SPINRAZA is used for the treatment of pediatric and adult patients with spinal muscular atrophy. QALSODY is approved for the treatment of Amyotrophic Lateral Sclerosis in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene, or SOD1-ALS. TEGSEDI is approved for the treatment of ATTRv-PN in adults. WAYLIVRA is approved as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk of acute, potentially fatal pancreatitis.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 20.05% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 705.14M.
Undervalued
The company’s latest PE is -50.72, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 172.84M shares, decreasing 6.54% quarter-over-quarter.
Held by HACAX
Star Investor HACAX holds 1.35K shares of this stock.
Analyst Rating
Based on
23
analysts
Buy
Current Rating
86.545
Target Price
+10.21%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Ionis Pharmaceuticals Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Ionis Pharmaceuticals Inc Info
Ionis Pharmaceuticals, Inc. develops six marketed medicines for serious diseases, including medicines for neurologic and cardiovascular diseases. Its marketed medicines consist of TRYNGOLZA, WAINUA (eplontersen), SPINRAZA (nusinersen), QALSODY (tofersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen). TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS). WAINUA is approved for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults. SPINRAZA is used for the treatment of pediatric and adult patients with spinal muscular atrophy. QALSODY is approved for the treatment of Amyotrophic Lateral Sclerosis in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene, or SOD1-ALS. TEGSEDI is approved for the treatment of ATTRv-PN in adults. WAYLIVRA is approved as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk of acute, potentially fatal pancreatitis.
Ticker SymbolIONS
CompanyIonis Pharmaceuticals Inc
CEOMonia (Brett P)
Websitehttps://www.ionis.com/
FAQs
What is the current price of Ionis Pharmaceuticals Inc (IONS)?
The current price of Ionis Pharmaceuticals Inc (IONS) is 81.540.
What is the symbol of Ionis Pharmaceuticals Inc?
The ticker symbol of Ionis Pharmaceuticals Inc is IONS.
What is the 52-week high of Ionis Pharmaceuticals Inc?
The 52-week high of Ionis Pharmaceuticals Inc is 86.150.
What is the 52-week low of Ionis Pharmaceuticals Inc?
The 52-week low of Ionis Pharmaceuticals Inc is 23.950.
What is the market capitalization of Ionis Pharmaceuticals Inc?
The market capitalization of Ionis Pharmaceuticals Inc is 13.14B.
What is the net income of Ionis Pharmaceuticals Inc?
The net income of Ionis Pharmaceuticals Inc is -453.90M.
Is Ionis Pharmaceuticals Inc (IONS) currently rated as Buy, Hold, or Sell?
According to analysts, Ionis Pharmaceuticals Inc (IONS) has an overall rating of Buy, with a price target of 86.545.
What is the Earnings Per Share (EPS TTM) of Ionis Pharmaceuticals Inc (IONS)?
The Earnings Per Share (EPS TTM) of Ionis Pharmaceuticals Inc (IONS) is -1.608.
Related Instruments
-2.11%
-0.87%
-4.01%
-1.21%
+2.19%
-0.34%
+1.38%
-3.37%
-2.96%
-0.04%
-2.99%
-0.50%
-1.41%
-0.80%
-1.16%
-0.05%
-1.39%
0.00%
+0.92%
-5.47%
